Ultragenyx Pharmaceutical Inc Q1 Loss increases, misses estimates

Ultragenyx Pharmaceutical Inc (RARE) revealed Loss for its first quarter that increased from the same period last year and missed the Street estimates.

The company's bottom line totaled -$152.3 million, or -$2.19 per share. This compares with -$136.1 million, or -$2.03 per share, in last year's first quarter.

Analysts on average had expected the company to earn -$1.76 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter fell 19.6% to $79.9 million from $99.4 million last year.

Ultragenyx Pharmaceutical Inc earnings at a glance (GAAP) :

-Earnings (Q1): -$152.3 Mln. vs. -$136.1 Mln. last year.
-EPS (Q1): -$2.19 vs. -$2.03 last year.
-Analyst Estimate: -$1.76
-Revenue (Q1): $79.9 Mln vs. $99.4 Mln last year.

For comments and feedback contact: editorial@rttnews.com

Follow RTT